DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,555,547 B1 Pamukcu Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,555,547 B1 Pamukcu Et Al USOO6555547B1 (12) United States Patent (10) Patent No.: US 6,555,547 B1 Pamukcu et al. (45) Date of Patent: Apr. 29, 2003 (54) METHOD FOR TREATING A PATIENT WITH 5,239,083 A 8/1993 Kumazawa et al. NEOPLASA BY TREATMENT WITH A 5,250,535 A 10/1993 Verheyden et al. VINCA ALKALOID DERVATIVE 5,254,571 A 10/1993 Coates et al. 5,358,952 A 10/1994 Moschel et al. (75) Inventors: Rifat Pamukcu, Spring House, PA 5,376,683 A 12/1994 Klar et al. (US); Joseph M. Lobacki, North 5,393,755 A 2/1995 Neustadt et al. s s 5,401.774 A 3/1995 Pamuckcu et al. Wales, PA (US) 5.439,895 A 8/1995 Lee et al. (73) Assignee: Cell Pathways, Inc., Horsham, PA (US) 3. A 19. t cal 5,614,530 A 3/1997 Kumar et al. (*) Notice: Subject to any disclaimer, the term of this 5,614,627 A 3/1997 Takase et al. patent is extended or adjusted under 35 5,674,876. A 10/1997 Gilbert et al. U.S.C. 154(b) by 0 days. 5,696,159 A 12/1997 Gross et al. 5,728,563 A 3/1998 Toshio et al. 5,731,167 A 3/1998 Stracke et al. (21) Appl. No.: 09/515,714 5,756.818 A 5/1998 Buchmann et al. (22) Filed: Feb. 28, 2000 5,798.246 A 8/1998 Au-Young et al. 5,798.373 A 8/1998 Warrellow 5,849,770 A 12/1998 Head et al. (51) Int. C.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A61K 31/44 5,852,035 A 12/1998 Pamukcu et al. (52) U.S. Cl. ....................... 514/283; 514/322; 514/321; 5,858,694. A 1/1999 Piazza et al. 514/468; 514/568 5,869,519 A 2/1999 Karanewsky et al. (58) Field of Search ................................. 514/321, 283, 5,874.440 A 2/1999 Pamukcu et al. 514/322, 468, 568 5,891,896 A 4/1999 Warrellow et al. 5,922,595 A 7/1999 Fisher et al. 5,932,423 A 8/1999 Au-Young et al. (56) References Cited 5,932,465. A 8/1999 Loughney U.S. PATENT DOCUMENTS 5,942,520 A 8/1999 Pamukcu et al. 5.948,779 A 9/1999 Sperl et al. 3,031,450 A 4/1962 Fischer et al. 3,161,654. A 12/1964 Shen FOREIGN PATENT DOCUMENTS 3,322,755 A 5/1967 Rochet al. 3,517,005 A 6/1970 Cronin et al. DE 3O38166 5/1981 3,594,480 A 7/1971 Cronin et al. DE 274218 12/1989 3,647.858 A 3/1972 Hinkley et al. EP O 330 004 A1 6/1989 3,654,349 A 4f1972 Shen et al. EP O 347146 A2 12/1989 3,780,040 A 12/1973 Schnettler et al. EP O 349239 A2 1/1990 3.812,127 A 5/1974 Cronin et al. EP O 351058 1/1990 3,819,631 A 6/1974 Broughton et al. EP O352960 A2 1/1990 3,865,840 A 2/1975 Carson (List continued on next page.) 3,920,636 A 11/1975 Takahasi et al. 4,001.237 A 1/1977 Partyka et al. OTHER PUBLICATIONS 4,001.238 A 1/1977 Partyka et al. 4,039,544 A 8/1977 Broughton et al. Charalambous et al., “Inhibition of colon cancer precursors 4,060.615 A 11/1977 Matier et al. in the rat by Sulindac Sulphone is not dependent on inhibition S; A 3E's y al. of prostaglandin Synthesis.”, Abstract to Journal of Gastro 4,098,788 A 7/1978 E.We al. enterology and Hepatology, vol. 11, No. 4, pp. 307-310, 4,101,548. A 7/1978 Crenshaw et al. 1996.* 4,102.885. A 7/1978 Crenshaw et al. Alberts et al., “Do NSAIDS exert their colon cancer chemo 4,138,561 A 2/1979 Crenshaw et al. prevention activities through the inhibition of mucosal pros 4,146,718 A 3/1979 Jenks et al. taglandin synthetase?”, Abstract to J. Cell. Biochem. (Suppl. 4,161,595 A 7/1979 Kaplan et al. 22), pp. 18–23, 1995.* 4,171,363 A 10/1979 Crenshaw et al. Windholz et al., Editor-in-Chief of the Merck Index, An E. A 3E Shaw et al. Encyclopedia of Chemicals, Drugs and Biologicals, 10Th 4423.075 A 12/1983 Dvornik et al. Edition, Jul. 21, 1986, Nos. 9784-9788 and 9789.* 4,460,5904,457,927 A 7/1984 M6Biere Iler et al. (ListLi continuedinued on next page.) 4,837.2394,460,591 A 6/19897/1984 BenjaminDeGraw et et al. al. Primary Examiner-Dwayne C. Jones 4,880,810 A 11/1989 Lowe, III et al. (74) Attorney, Agent, or Firm-Robert W. Stevenson 4.885,301 A 12/1989 Coates (57) ABSTRACT 4923,874 A 5/1990 McMahon et al. 4,971,972 A 11/1990 Doll et al. This invention provides a method for treating a patient with 5,073,559 A 12/1991 Coates neoplasia by an adjuvant therapy that includes treatment ... A 3 E3 Althit al. with an antineoplastic Vinca alkaloid derivative. 5,175,151 A 12/1992 Afonso et al. 5,223,501 A 6/1993 Chakravarty et al. 17 Claims, 29 Drawing Sheets US 6,555,547 B1 Page 2 FOREIGN PATENT DOCUMENTS Antonenko S.G. et al., The role of the components of the cyclic nucleotide System in N-nitroSodiethylamine-induced EP O 395328 A2 10/1990 EP O 428268 A2 5/1991 hepatic carcinogenesis in rats (Article in Russian), Eksp. EP O 463756 A1 1/1992 Onkol. 1990; 12(5):18-21. EP O 48.5157 A2 5/1992 Badrieh, Y., et al., Chem. Ber, vol. 125, pp. 667-674 (1992). EP O 485.158 A2 5/1992 Barnett, Mary S. et al., Initial biochemical and functional EP O 485.171 A2 5/1992 characterization of cyclic nucleotide phosphodiesterase EP O 485172 A2 5/1992 isozymes in canine colonic Smooth muscle (Abstract Only), EP O 485.173 A2 5/1992 EP O 508586 A1 10/1992 J. Pharmacol. Exp. Ther..., 264(2) pp. 801-812 (1993). EP O 526004 A1 2/1993 Basu, S. and Kolesnick, R. StreSS Signals for apoptosis: EP O 607439 A1 7/1994 ceramide and c-Jun kinase. Oncogene, 17: 3277-85, 1998. EP O 7433O4 A1 5/1996 Belousova, A. K. et al., Role of cyclic nucleotides in tumor EP O 722937 A1 7/1996 growth regulation, (Article written in Russian) Vestn. Akad. GB 807826 1/1959 Med, Nauk SSSR (1980), (6), 86–9. GB 2063249 A 6/1981 Beltman, Jerlyn et al., Characterization of cyclic nucleotide JP 56-53659 A 5/1981 phosphodiesterases with cyclic GMP analogs: topology of JP 57-167974. A 10/1982 the catalytic domains, Mol. Pharmacol. (1995), 47(2), JP 8-311035 11/1996 330-9. WO WO 92/03419 3/1992 WO WO 93/07 149 4/1993 Bergstrand, Hakan et al., Effects of Antiallergic Agents, WO WO 93/12095 6/1993 Compound 48/80, and Some Reference Inhibitors on the WO WO 94/05661 3/1994 Activity of Partially Purified Human Lung Tissue Adenosine WO WO 94/19351 9/1994 Cyclic 3',5'-Monophosphate and Guanosine Cyclic WO WO 94/29277 12/1994 3',5'-Monophosphate Phosphodiesterase, Molecular Phar WO WO 95 18969 A 7/1995 macology, 13, pp. 38–43 (1976). WO WO95/26743 10/1995 WO WO 97/03070 1/1997 Biddle, William et al., Antineoplastic Effect of the Pyrimi WO WO 97/03985 2/1997 do-Pyrimidine Derivative: RA 233, Pathologie Biologie, WO WO 97/24334 7/1997 Jan., 1984, pp. 9-13. WO WO 98/14448 4/1998 Bjamason et al., Gastroenterology, Vol. 94, No. 4, pp. WO WO 98/15530 4/1998 1070–1074 (1988). WO WO 98/16224 4/1998 Blaya, C. et al., Effect of the protein kinase inhibitors, WO WO 98/16521 4/1998 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 and WO WO 98/17668 4/1998 WO WO 98/08848 5/1998 N-(2-methylaminoethyl)-5-isoquinoline-sulfonamide WO WO 98/23597 6/1998 H-8 on Lewis lung carcinoma tumor progression, European WO WO 98/381.68 9/1998 Journal of Pharmacology, 354, pp. 99-104 (1998). WO WO 96/32379 10/1998 Brogden, R.N. et al., Drugs, vol. 16, pp. 97-114 (1978). Broughton, B.J. et al., Antiallergic Activity of OTHER PUBLICATIONS 2-Phenyl-8-azapruin-6-ones, Journal of Medicinal Chem Earnest, D. et al., PiroXicam and Other Cyclooxygenase istry, vol. 18, No. 11, pp. 1117–1118 (1975). Inhibitors: Potential for Cancer Chemoprevention, Journal Butt, E., Eigenthaler, M., and Genieser, H. G. of Cellular Biochemistry, Supplement 161:156–166, 1992.* (Rp)-8-pCPT-cGMPs, a novel c(GMP-dependent protein Neit “Oncologic, Endocrine & Metabolic-Treatments, kinase inhibitor. Eur J Pharmacol, 269: 265–8, 1994. topics and trends in ovarian cancer, Exp. Opin. Invest. Butt, Elke et al., Characterization of cyclic nucleotide phos Drugs 4(12): 1205-1216, (1995).* phodiesterases with cyclic AMP analogs: topology of the Ahlstrom, M., Lamberg-Allardt, C., Regulation of adenos catalytic sites and comparison with other cyclic AMP-bind ine 3',5'-cyclic monophosphate (cAMP) accumulation in ing proteins, Mol. Pharmacol. (1995), 47(2), 340-7. UMR-106 osteoblastlike cells: role of cAMP-phosphodi Cardone, M. H., Salvesen, G. S., Widmann, C., Johnson, G., esterase and cAMP efflux, Biochem. Pharmacol. (1999), and Frisch, S. M. The regulation of anoikis: MEKK-1 58(8), 1335–1340.
Load more

Recommended publications
  • Practice Parameters for the Treatment of Patients with Dominantly Inherited Colorectal Cancer
    Practice Parameters For The Treatment Of Patients With Dominantly Inherited Colorectal Cancer Diseases of the Colon & Rectum 2003;46(8):1001-1012 Prepared by: The Standards Task Force The American Society of Colon and Rectal Surgeons James Church, MD; Clifford Simmang, MD; On Behalf of the Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons is dedicated to assuring high quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The standards committee is composed of Society members who are chosen because they have demonstrated expertise in the specialty of colon and rectal surgery. This Committee was created in order to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus. This is accompanied by developing Clinical Practice Guidelines based on the best available evidence. These guidelines are inclusive, and not prescriptive. Their purpose is to provide information on which decisions can be made, rather than dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, health care workers, and patients who desire information about the management of the conditions addressed by the topics covered in these guidelines. Practice Parameters for the Treatment of Patients With Dominantly Inherited Colorectal Cancer Inherited colorectal cancer includes two main syndromes in which predisposition to the disease is based on a germline mutation that may be transmitted from parent to child.
    [Show full text]
  • Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
    Review Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Joel Mintz 1,†, Anastasia Vedenko 2,†, Omar Rosete 3 , Khushi Shah 4, Gabriella Goldstein 5 , Joshua M. Hare 2,6,7 , Ranjith Ramasamy 3,6,* and Himanshu Arora 2,3,6,* 1 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA; [email protected] 2 John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] (A.V.); [email protected] (J.M.H.) 3 Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] 4 College of Arts and Sciences, University of Miami, Miami, FL 33146, USA; [email protected] 5 College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA; [email protected] 6 The Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 7 Department of Medicine, Cardiology Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA * Correspondence: [email protected] (R.R.); [email protected] (H.A.) † These authors contributed equally to this work. Abstract: Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumori- Citation: Mintz, J.; Vedenko, A.; genic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the Rosete, O.; Shah, K.; Goldstein, G.; level of production, the oxidative/reductive (redox) environment in which this radical is generated, Hare, J.M; Ramasamy, R.; Arora, H.
    [Show full text]
  • New Drugs Are Not Enough‑Drug Repositioning in Oncology: an Update
    INTERNATIONAL JOURNAL OF ONCOLOGY 56: 651-684, 2020 New drugs are not enough‑drug repositioning in oncology: An update ROMINA GABRIELA ARMANDO, DIEGO LUIS MENGUAL GÓMEZ and DANIEL EDUARDO GOMEZ Laboratory of Molecular Oncology, Science and Technology Department, National University of Quilmes, Bernal B1876, Argentina Received August 15, 2019; Accepted December 16, 2019 DOI: 10.3892/ijo.2020.4966 Abstract. Drug repositioning refers to the concept of discov- 17. Lithium ering novel clinical benefits of drugs that are already known 18. Metformin for use treating other diseases. The advantages of this are that 19. Niclosamide several important drug characteristics are already established 20. Nitroxoline (including efficacy, pharmacokinetics, pharmacodynamics and 21. Nonsteroidal anti‑inflammatory drugs toxicity), making the process of research for a putative drug 22. Phosphodiesterase-5 inhibitors quicker and less costly. Drug repositioning in oncology has 23. Pimozide received extensive focus. The present review summarizes the 24. Propranolol most prominent examples of drug repositioning for the treat- 25. Riluzole ment of cancer, taking into consideration their primary use, 26. Statins proposed anticancer mechanisms and current development 27. Thalidomide status. 28. Valproic acid 29. Verapamil 30. Zidovudine Contents 31. Concluding remarks 1. Introduction 2. Artesunate 1. Introduction 3. Auranofin 4. Benzimidazole derivatives In previous decades, a considerable amount of work has been 5. Chloroquine conducted in search of novel oncological therapies; however, 6. Chlorpromazine cancer remains one of the leading causes of death globally. 7. Clomipramine The creation of novel drugs requires large volumes of capital, 8. Desmopressin alongside extensive experimentation and testing, comprising 9. Digoxin the pioneer identification of identifiable targets and corrobora- 10.
    [Show full text]
  • Antiproliferative and Proapoptotic Activities of Anthocyanin and Anthocyanidin Extracts from Blueberry Fruits on B16-F10 Melanoma Cells
    FOOD & NUTRITION RESEARCH, 2017 VOL. 61, 1325308 https://doi.org/10.1080/16546628.2017.1325308 ORIGINAL ARTICLE Antiproliferative and proapoptotic activities of anthocyanin and anthocyanidin extracts from blueberry fruits on B16-F10 melanoma cells Erlei Wanga, Yanjun Liua, Caina Xub and Jingbo Liua aCollege of Food Science and Engineering, Jilin University, Changchun, Jilin, PR China; bKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, PR China ABSTRACT ARTICLE HISTORY Background: Anthocyanins have been proven to affect multiple cancer-associated processes in Received 29 January 2017 different cancer cell lines. However, relatively few studies have investigated the effects of blueberry Accepted 26 April 2017 anthocyanins on metastatic melanoma. Thus, this study focuses on evaluating the chemopreventive KEYWORDS potential of blueberry anthocyanins and their aglycones (anthocyanidins) in B16-F10 melanoma cells. Blueberry; anthocyanins; Methods: Blueberry anthocyanin and anthocyanidin extracts were prepared mainly by combined anthocyanidins; cell chromatography techniques. Their antiproliferative and proapoptotic effects on B16-F10 cells apoptosis; cell cycle were evaluated by MTT assay, calcein acetoxymethyl ester/propidium iodide (calcein-AM/PI) staining, and flow cytometry of the cell cycle and apoptosis. Results: The MTT and calcein-AM/PI staining results showed that both anthocyanin (purity of 62.5%) and anthocyanidin (75.1%) extracts could significantly inhibit the viability and proliferation of B16- F10 cells in a dose-dependent manner, while anthocyanidin extracts exhibited significantly higher (p < 0.05) cytotoxicity than anthocyanin extracts. Furthermore, anthocyanin and anthocyanidin extracts blocked cell cycle procession at the G0/G1 phase below 400 and 200 μg/mL, and induced early apoptosis below 400 and 300 μg/mL, respectively.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Annexes to the Annual Report of the European Medicines Agency 2014
    Annexes to the annual report of the European Medicines Agency 2014 Table of contents Annex 1 – Members of the Management Board ............................................................................. 2 Annex 2 – Members of the Committee for Medicinal Products for Human Use ................................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ...................................... 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ............................... 8 Annex 5 – Members of the Committee on Orphan Medicinal Products ............................................ 10 Annex 6 – Members of the Committee on Herbal Medicinal Products .............................................. 12 Annex 07 – Committee for Advanced Therapies .......................................................................... 14 Annex 8 – Members of the Paediatric Committee ........................................................................ 16 Annex 9 – Working parties and working groups .......................................................................... 18 Annex 10 – CHMP opinions in 2014 on medicinal products for human use ...................................... 22 Annex 11 – CVMP opinions in 2014 on medicinal products for veterinary use .................................. 36 Annex 12 – COMP opinions in 2014 on designation of orphan medicinal products ............................ 41 Annex 13 – HMPC European Union herbal monographs in 2014....................................................
    [Show full text]
  • The Old, the New, and the Future
    Cancer Biol Med 2018. doi: 10.20892/j.issn.2095-3941.2018.0030 REVIEW G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future Angel Mauricio Castro-Gamero1, Julia Alejandra Pezuk2, María Sol Brassesco3, Luiz Gonzaga Tone4,5 1Human Genetics Laboratory, Institute of Natural Sciences, Federal University of Alfenas (UNIFAL-MG), Alfenas 37130-001, Brazil; 2Biotechnology and Innovation in Health Program and Pharmacy Program, Anhanguera University São Paulo (UNIAN- SP), São Paulo 05145-200, Brazil; 3Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-901, Brazil; 4Department of Pediatrics; 5Department of Genetics, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto 14049-900, Brazil ABSTRACT Glioblastoma (GBM) is one of the deadliest tumors and has a median survival of 3 months if left untreated. Despite advances in rationally targeted pharmacological approaches, the clinical care of GBM remains palliative in intent. Since the majority of altered signaling cascades involved in cancer establishment and progression eventually affect cell cycle progression, an alternative approach for cancer therapy is to develop innovative compounds that block the activity of crucial molecules needed by tumor cells to complete cell division. In this context, we review promising ongoing and future strategies for GBM therapeutics aimed towards G2/M inhibition such as anti-microtubule agents and targeted therapy against G2/M regulators like cyclin-dependent kinases, Aurora inhibitors, PLK1, BUB, 1, and BUBR1, and survivin. Moreover, we also include investigational agents in the preclinical and early clinical settings. Although several drugs were shown to be gliotoxic, most of them have not yet entered therapeutic trials.
    [Show full text]
  • Sildenafil Increases Chemotherapeutic Efficacy of Doxorubicin in Prostate
    Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction Anindita Dasa,1, David Durranta, Clint Mitchellb, Eric Maytona, Nicholas N. Hokea, Fadi N. Sallouma, Margaret A. Parkb, Ian Qureshia, Ray Leeb, Paul Dentb, and Rakesh C. Kukrejaa,1 aDivision of Cardiology, Department of Internal Medicine, Virginia Commonwealth University Pauley Heart Center and bDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University Medical Center, Richmond, VA 23298 Edited* by Herbert Weissbach, Florida Atlantic University, Boca Raton, FL, and approved August 17, 2010 (received for review May 25, 2010) We have shown that the potent phosphodiesterase-5 (PDE-5) enocarcinoma, bladder squamous carcinoma, and lung cancers inhibitor sildenafil (Viagra) induces a powerful effect on reduction (15–17), suggesting its potential role in controlling tumor cell of infarct size following ischemia/reperfusion injury and improve- growth and death. Sildenafil and vardenafil suppress tumor cell ment of left ventricular dysfunction in the failing heart after growth and induce caspase-dependent apoptosis in B-cell chronic myocardial infarction or doxorubicin (DOX) treatment. In the present lymphatic leukemia (18, 19). Another PDE-5 inhibitor, exisulind study, we further investigated the potential effects of sildenafilon (sulindac sulfone), and its higher affinity analogs also induce ap- improving antitumor efficacy of DOX in prostate cancer. Cotreat- optosis and inhibit cell proliferation in colon tumor cells lines by ment with sildenafil enhanced DOX-induced apoptosis in PC-3 and activating PKG and phosphorylation of β-catenin (20). These DU145 prostate cancer cells, which was mediated by enhanced gen- compounds also inhibit growth and induce apoptosis in several eration of reactive oxygen species, up-regulation of caspase-3 and human prostate cancer cell lines and prostate cancer xenografts in caspase-9 activities, reduced expression of Bcl-xL, and phosphoryla- nude mice (21–23).
    [Show full text]
  • Low-Dose Anti-Inflammatory Combinatorial Therapy Reduced Cancer Stem Cell Formation in Patient-Derived Preclinical Models for Tumour Relapse Prevention
    Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Khoo, Bee Luan, Gianluca Grenci, Joey Sze Yun Lim et al. "Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention." British Journal of Cancer (February 2019) 120:407-423 © 2019, The Author(s). As Published https://dx.doi.org/10.1038/s41416-018-0301-9 Version Final published version Citable link https://hdl.handle.net/1721.1/125700 Terms of Use Creative Commons Attribution 4.0 International license Detailed Terms https://creativecommons.org/licenses/by/4.0/ www.nature.com/bjc ARTICLE Translational Therapeutics Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention Bee Luan Khoo1, Gianluca Grenci2,3, Joey Sze Yun Lim1, Yan Ping Lim4, July Fong5, Wei Hseun Yeap6, Su Bin Lim3,7, Song Lin Chua8, Siew Cheng Wong6, Yoon-Sim Yap9, Soo Chin Lee10,11, Chwee Teck Lim1,2,3,12 and Jongyoon Han1,13 BACKGROUND: Emergence of drug-resistant cancer phenotypes is a challenge for anti-cancer therapy. Cancer stem cells are identified as one of the ways by which chemoresistance develops. METHOD: We investigated the anti-inflammatory combinatorial treatment (DA) of doxorubicin and aspirin using a preclinical microfluidic model on cancer cell lines and patient-derived circulating tumour cell clusters. The model had been previously demonstrated to predict patient overall prognosis.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub
    US 20090226431A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub. Date: Sep. 10, 2009 (54) TREATMENT OF CANCER AND OTHER Publication Classification DISEASES (51) Int. Cl. A 6LX 3/575 (2006.01) (76)76) InventorInventor: Nabilabil Habib,Habib. Beirut (LB(LB) C07J 9/00 (2006.01) Correspondence Address: A 6LX 39/395 (2006.01) 101 FEDERAL STREET A6IP 29/00 (2006.01) A6IP35/00 (2006.01) (21) Appl. No.: 12/085,892 A6IP37/00 (2006.01) 1-1. (52) U.S. Cl. ...................... 424/133.1:552/551; 514/182: (22) PCT Filed: Nov.30, 2006 514/171 (86). PCT No.: PCT/US2O06/045665 (57) ABSTRACT .."St. Mar. 6, 2009 The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3B.5C,6C.-triol), its production, its use, and to methods of treating neoplasms and other tumors as Related U.S. Application Data well as other diseases including hypercholesterolemia, (60) Provisional application No. 60/741,725, filed on Dec. autoimmune diseases, viral diseases (e.g., hepatitis B, hepa 2, 2005. titis C, or HIV), and diabetes. F2: . - 2 . : F2z "..., . Cz: ".. .. 2. , tie - . 2 2. , "Sphagoshgelin , , re Cls Phosphatidiglethanolamine * - 2 .- . t - r y ... CBs .. A . - . Patent Application Publication Sep. 10, 2009 Sheet 1 of 16 US 2009/0226431 A1 E. e'' . Phosphatidylcholine. " . Ez'.. C.2 . Phosphatidylserias. * . - A. z' C. w E. a...2 .". is 2 - - " - B 2. Sphingoshgelin . Cls Phosphatidglethanglamine Figure 1 Patent Application Publication Sep. 10, 2009 Sheet 2 of 16 US 2009/0226431 A1 Chile Phosphater Glycerol Phosphatidylcholine E.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]